Multivariable analysis in the training set (n = 316) of the 2022 ELN adverse-risk patients
| Gene mutation . | n . | Beta . | SE of beta . | HR . | 95% CI for HR . | P value . |
|---|---|---|---|---|---|---|
| IDH2 | 52 | −0.42 | 0.18 | 0.65 | 0.46-0.94 | .022 |
| KRAS | 24 | 0.55 | 0.24 | 1.74 | 1.09-2.76 | .019 |
| MLL2 | 51 | 0.36 | 0.17 | 1.43 | 1.03-1.99 | .035 |
| TP53 | 113 | 0.64 | 0.13 | 1.90 | 1.47-2.47 | <.001 |
| Gene mutation . | n . | Beta . | SE of beta . | HR . | 95% CI for HR . | P value . |
|---|---|---|---|---|---|---|
| IDH2 | 52 | −0.42 | 0.18 | 0.65 | 0.46-0.94 | .022 |
| KRAS | 24 | 0.55 | 0.24 | 1.74 | 1.09-2.76 | .019 |
| MLL2 | 51 | 0.36 | 0.17 | 1.43 | 1.03-1.99 | .035 |
| TP53 | 113 | 0.64 | 0.13 | 1.90 | 1.47-2.47 | <.001 |
SE, Standard error